{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009781","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.666891+00:00","generated_at":"2026-05-16T10:52:54.564756+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Therapeutics accelerates EMPEROR enrollment, expects Phase 3 data in mid-2027, cash $391.7M","bullets":["Enrollment of 150 patients in Phase 3 EMPEROR study expected to complete in Q2 2026, accelerated from prior timeline.","Phase 3 data readout planned for mid-2027; rolling NDA submission to initiate in first half 2027.","FDA multidisciplinary meeting held; no immediate program changes, but discussions ongoing for expedited pathways.","Cash, equivalents and marketable securities $391.7M as of Dec 31, 2025; plus Biogen proceeds funds operations into 2028.","Nearly 330 potential study candidates identified globally; ~60 in screening, ~60 randomized/dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009781","json":"https://secwatch.observer/filing/0001193125-26-009781.json","markdown":"https://secwatch.observer/filing/0001193125-26-009781.md","text":"https://secwatch.observer/filing/0001193125-26-009781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526009781/0001193125-26-009781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526009781/d36198d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:54.564756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}